Clinical trials: Locally Advanced Gastric Cancer
HER2-Positive Solid Tumor
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
- Trial name
- NCT05523947
- Testing
- YH32367
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 147 people
- Sponsor
- Yuhan Corporation
Gastric Cancer
Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients
The primary objective of the study is to assess the safety and tolerability of cediranib in combination with Cisplatin plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese patients with previously untreated locally advanced…
- Trial name
- NCT00960349
- Testing
- Cediranib, Cisplatin, S-1
- Where
- 4 sites in Japan
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Gastroesophageal-junction Cancer, Monoclonal Antibody
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with…
- Conditions
- Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT06532006
- Testing
- HLX22, Pembrolizumab, Trastuzumab
- Where
- 208 sites in United States, Argentina and 15 more
- Volunteers
- 550 people
- Sponsor
- Shanghai Henlius Biotech
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
This study will evaluate the efficacy and safety of Herceptin in patients with metastatic or advanced gastric cancer with disease progression during platinum-based or 5-fluoropyrimidine-based chemotherapy.
- Trial name
- NCT02005484
- Testing
- Trastuzumab
- Where
- 12 sites in Austria, Germany
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer
- Trial name
- NCT00237900
- Testing
- Gefitinib, 5-fluorouracil, leucovorin and radiotherapy
- Where
- Finland
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Cancer of Stomach, Gastroesophageal Cancer
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
The purpose of this study is to evaluate the safety and efficacy of pegamotecan (PEG-camptothecin) in patients with pathologically-diagnosed locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal…
- Trial name
- NCT00080002
- Testing
- Pegamotecan
- Sponsor
- Enzon Pharmaceuticals, Inc.
Gastric Cancer
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal…
- Trial name
- RILOMET-1 (NCT01697072)
- Testing
- Rilotumumab, Epirubicin, Cisplatin
- Where
- 189 sites in United States, Australia and 25 more
- Volunteers
- 609 people
- Sponsor
- Amgen
Gastric Cancer, Gastroesophageal Junction Cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC)…
- Trial name
- NCT06731478
- Testing
- Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab
- Where
- 250 sites in United States, Argentina and 24 more
- Volunteers
- 726 people
- Sponsor
- Daiichi Sankyo